All News
No Benefit to More Intensive Urate Lowering in Gout
While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.
Read Article
Consensus Best Practices for Virtual Care in Rheumatology
The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.
Read Article
ACR Fellow Training Subcommittee Report on Pandemic Experiences
Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training.
Read Article
Is Alzheimer's Risk Lower With TNF Inhibitors?
d
MedPage Today
Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.
Read Article
QD Clinic - PsA Lessons from the Clinic
LFT Elevations may be considered differently in PsA patients
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Laura Coates discusses Precision Medicine in PsA.
https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH
Links:
Dr. John Cush RheumNow ( View Tweet)
The value of COVID Vaccine after COVID infection - Vax Effx after COVID=445% after 2 doses & 58% after booster during Delta COVID. During Omicron, 35% effect after 2 doses and 68% after a booster dose - best protection conferred by booster https://t.co/VXi70r2nS3 https://t.co/Oeuet3pudD
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic
Reasons why PsA patient can lose biologic efficacy and what to do about it
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Combined Clinics for PsA
Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week.
https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH
Links:
Dr. John Cush RheumNow ( View Tweet)
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF
Links:
Dr. John Cush RheumNow ( View Tweet)
How long does a good response last to a biologic?
How and When to distinguish between flares and intercurrent illness.
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/ZIWQysY5dd https://t.co/RZrS6FfUTV
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367
Links:
Dr. John Cush RheumNow ( View Tweet)
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 1144 consecutive inflammatory myositis (IIM) pts shows a 2.3% risk of venous thrombolic events. 54% of VTE occurred within 6 mos of IIM Dx. Predictors included malignancy, infection, longer steroid use , higher Dz activity https://t.co/DCH4Iuy2FS https://t.co/uNc6i6L7JJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Cell has a novel analysis using single-cell analysis of skin/blood from 56 controls & 97 diffuse systemic sclerosis pts, finding stromal abnormalities in LGR5+-scleroderma-assoc fibroblasts (ScAFs). ScAFs are decreased early & progressively https://t.co/Khxejd1fnq https://t.co/OrMAJnPTZt
Links:
Dr. John Cush RheumNow ( View Tweet)
ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1
Links:
Dr. John Cush RheumNow ( View Tweet)
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/M6y5Gezhjs https://t.co/HYoI3pExRm
Links:
Dr. John Cush RheumNow ( View Tweet)
